|
1
|
Gotto AM Jr and Brinton EA: Assessing low
levels of high-density lipoprotein cholesterol as a risk factor in
coronary heart disease: A working group report and update. J Am
Coll Cardiol. 43:717–724. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Assmann G and Gotto AM Jr: Hdl cholesterol
and protective factors in atherosclerosis. Circulation 109 (23
Suppl 1). III8–III14. 2004.
|
|
3
|
Miller NE: High-density lipoprotein: A
major risk factor for coronary atherosclerosis. Baillieres Clin
Endocrinol Metab. 1:603–622. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu N and Dahlbäck B: A novel human
apolipoprotein (apom). J Biol Chem. 274:31286–31290. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luo G, Zhang X, Nilsson-Ehle P and Xu N:
Apolipoprotein M. Lipids Health Dis. 3:212004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang XY, Dong X, Zheng L, Luo GH, Liu YH,
Ekström U, Nilsson-Ehle P, Ye Q and Xu N: Specific tissue
expression and cellular localization of human apolipoprotein M as
determined by in situ hybridization. Acta Histochem. 105:67–72.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wolfrum C, Poy MN and Stoffel M:
Apolipoprotein M is required for prebeta-HDL formation and
cholesterol efflux to HDL and protects against atherosclerosis. Nat
Med. 11:418–422. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang X, Zhu Z, Luo G, Zheng L,
Nilsson-Ehle P and Xu N: Liver X receptor agonist downregulates
hepatic apoM expression in vivo and in vitro. Biochem Biophys Res
Commun. 371:114–117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Human
Pathology. 40:1512–1515. 2009. View Article : Google Scholar
|
|
11
|
Ríos-Marco P, Ríos A, Jiménez-López JM,
Carrasco MP and Marco C: Cholesterol homeostasis and autophagic
flux in perifosine-treated human hepatoblastoma HepG2 and
glioblastoma U-87 MG cell lines. Biochem Pharmacol. 96:10–19. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin FY, Kamanna VS and Kashyap ML: Niacin
accelerates intracellular ApoB degradation by inhibiting
triacylglycerol synthesis in human hepatoblastoma (HepG2) cells.
Arterioscler Thromb Vasc Biol. 19:1051–1059. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu D, Ganji SH, Kamanna VS and Kashyap
ML: Effect of gemfibrozil on apolipoprotein B secretion and
diacylglycerol acyltransferase activity in human hepatoblastoma
(HepG2) cells. Atherosclerosis. 164:221–228. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carlson LA: Nicotinic acid: The
broad-spectrum lipid drug. A 50th anniversary review. J Intern Med.
258:94–114. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McKenney J: New perspectives on the use of
niacin in the treatment of lipid disorders. Arch Intern Med.
164:697–705. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brown BG, Zhao XQ, Chait A, Fisher LD,
Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P,
et al: Simvastatin and niacin, antioxidant vitamins, or the
combination for the prevention of coronary disease. N Engl J Med.
345:1583–1592. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Taylor AJ, Sullenberger LE, Lee HJ, Lee JK
and Grace KA: Arterial Biology for the Investigation of the
Treatment Effects of Reducing Cholesterol (ARBITER) 2: A
double-blind, placebo-controlled study of extended-release niacin
on atherosclerosis progression in secondary prevention patients
treated with statins. Circulation. 110:3512–3517. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kamanna VS and Kashyap ML: Mechanism of
action of niacin on lipoprotein metabolism. Curr Atheroscler Rep.
2:36–46. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu ZH and Zhao SP: Niacin promotes
cholesterol efflux through stimulation of the
PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes.
Pharmacology. 84:282–287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ulven SM, Dalen KT, Gustafsson JA and Nebb
HI: LXR is crucial in lipid metabolism. Prostaglandins Leukot
Essent Fatty Acids. 73:59–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Valledor AF: The innate immune response
under the control of the LXR pathway. Immunobiology. 210:127–132.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bensinger SJ and Tontonoz P: Integration
of metabolism and inflammation by lipid-activated nuclear
receptors. Nature. 454:470–477. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Steffensen KR and Gustafsson JA: Putative
metabolic effects of the liver X receptor (LXR). Diabetes. 53
(Suppl 1):S36–S42. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chawla A, Boisvert WA, Lee CH, Laffitte
BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, et
al: A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in
cholesterol efflux and atherogenesis. Mol Cell. 7:161–171. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schwartz K, Lawn RM and Wade DP: ABC1 gene
expression and ApoA-I-mediated cholesterol efflux are regulated by
LXR. Biochem Biophys Res Commun. 274:794–802. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luo Y and Tall AR: Sterol upregulation of
human CETP expression in vitro and in transgenic mice by an LXR
element. J Clin Invest. 105:513–520. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sato M, Kawata Y, Erami K, Ikeda I and
Imaizumi K: LXR agonist increases the lymph HDL transport in rats
by promoting reciprocally intestinal ABCA1 and apo A-I mRNA levels.
Lipids. 43:125–131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Khovidhunkit W, Moser AH, Shigenaga JK,
Grunfeld C and Feingold KR: Endotoxin down-regulates ABCG5 and
ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine
macrophages: Differential role of LXR. J Lipid Res. 44:1728–1736.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Arkensteijn BW, Berbée JF, Rensen PC,
Nielsen LB and Christoffersen C: The apolipoprotein
m-sphingosine-1-phosphate axis: Biological relevance in lipoprotein
metabolism, lipid disorders and atherosclerosis. Int J Mol Sci.
14:4419–4431. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ruiz M, Frej C, Holmér A, Guo LJ, Tran S
and Dahlbäck B: High-density lipoprotein-associated apolipoprotein
M limits endothelial inflammation by delivering
sphingosine-1-phosphate to the sphingosine-1-phosphate receptor 1.
Arterioscler Thromb Vasc Biol. 37:118–129. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ruiz M, Okada H and Dahlbäck B:
HDL-associated ApoM is anti-apoptotic by delivering sphingosine
1-phosphate to S1P1 & S1P3 receptors on vascular endothelium.
Lipids Health Dis. 16:362017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Frej C, Mendez AJ, Ruiz M, Castillo M,
Hughes TA, Dahlbäck B and Goldberg RB: A shift in ApoM/S1P between
HDL-particles in women with type 1 diabetes mellitus is associated
with impaired anti-inflammatory effects of the ApoM/S1P complex.
Arterioscler Thromb Vasc Biol. 37:1194–1205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Błachnio-Zabielska A, Baranowski M, Wójcik
B and Górski J: Reduction of ceramide de novo synthesis in solid
tissues changes sphingolipid levels in rat plasma, erythrocytes and
platelets. Adv Med Sci. 61:72–77. 2016. View Article : Google Scholar : PubMed/NCBI
|
